Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Creative Planning acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 14,118 shares of the company’s stock, valued at approximately $28,000.

Other large investors also recently bought and sold shares of the company. Principal Financial Group Inc. purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $48,000. Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $97,000. SG Americas Securities LLC acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $129,000. Privium Fund Management B.V. acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $213,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Taysha Gene Therapies by 109.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock worth $298,000 after purchasing an additional 69,487 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 7.5 %

Shares of NASDAQ TSHA opened at $2.21 on Thursday. The firm has a market cap of $452.92 million, a price-to-earnings ratio of -11.15 and a beta of 0.44. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies, Inc. has a 52-week low of $1.19 and a 52-week high of $4.32. The business’s 50 day moving average is $1.97 and its two-hundred day moving average is $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $3.62 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. Research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TSHA shares. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Canaccord Genuity Group decreased their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus target price of $6.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.